Single ascending dose study of ASC47 monotherapy in subjects with obesity
Latest Information Update: 12 Nov 2024
Price :
$35 *
At a glance
- Drugs ASC 47 (Primary)
- Indications Non-alcoholic steatohepatitis
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 12 Nov 2024 New trial record
- 07 Nov 2024 According to Ascletis media release, topline data are expected in the first quarter of 2025.